Study of Dasatinib, Androgen Deprivation Therapy and Radiation

PATIENT ELIGIBILITY

-Conditions for Patient Eligibility

Each patient must meet all of the following inclusion criteria to be enrolled in the study:

* Histologically or pathologically confirmed adenocarcinoma of the prostate to be treated with radiation therapy and hormone therapy.
* Intermediate, high or very high risk disease

  * Intermediate-risk disease (clinical T2b or T2c stage or PSA 10 to 20 ng/mL or Gleason score 7)
  * High-risk disease (Gleason score 8 to 10, serum PSA \> 20 ng/mL or T3a disease)
  * Very high-risk disease (T3b or T4)
* No prior pelvic or prostate radiation or chemotherapy for prostate cancer.
* Clinically negative lymph nodes as established by imaging (pelvic CT or pelvic MR), nodal sampling or dissection within 8 weeks prior to registration. Patients with lymph nodes equivocal or questionable by imaging are eligible if the nodes are \< 1.5 cm.
* Bone scan within 12 weeks prior to registration. Equivocal bone scan findings are allowed if plain films are negative for metastasis.
* ECOG performance status 0-1
* Age \> 18
* Required entry laboratory parameters within 14 days of study entry: Granulocytes ≥ 1500/µl; platelet count ≥ 100,000/µl; Hgb \> 8.0 g/dl; Creatinine \< 1.5 x the institutional ULN, mg/dl; Bilirubin ≤ 2x institutional upper limit of normal; AST ≤ 2.5 x upper limit of normal, Serum Na+, K+, Mg2+, Phosphate and Calcium within institutional normal range; PT and PTT \< 1.5 ULN
* Life expectancy of at least 1 year
* No concurrent anticancer therapy.
* Peripheral neuropathy must be ≤ Grade 2
* A male subject of fathering potential must use an adequate method of contraception throughout the study \[and for at least 4 weeks after the last dose of study drug\].
* Ability to take oral medication (dasatinib must be swallowed whole)
* Signed study-specific consent form prior to study entry

Conditions for Patient Ineligibility

Patients meeting any of the following exclusion criteria are not to be enrolled in the study:

* Evidence of distant metastases (M1).
* Prior radical prostatectomy, cryosurgery for prostate cancer, or bilateral orchiectomy for any reason
* PSA \> 150
* Pathologically positive lymph nodes or nodes \> 1.5 cm on imaging
* Major medical or psychiatric illness which, in the investigator's opinion, would prevent completion of treatment and would interfere with follow-up.
* Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable.
* Prior radiotherapy, including brachytherapy, to the region of the study cancer that would result in overlap of radiation therapy fields
* Medical History and Concurrent Diseases
* No malignancy \[other than the one treated in this study\] which required radiotherapy or systemic treatment within the past 5 years.
* Concurrent medical condition which may increase the risk of toxicity, including:
* Pleural or pericardial effusion of any grade
* Cardiac Symptoms; any of the following should be considered for exclusion:
* History of significant bleeding disorder unrelated to cancer, including:
* No history of pulmonary hypertension